This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Labcorp Q4 Earnings & Revenues Beat, Margins Down, Stock Tumbles
by Zacks Equity Research
LH delivers better-than-expected revenues and earnings in the fourth quarter of 2024.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Hologic Q1 Earnings Beat, Stock Falls on Dismal '25 Sales Guidance
by Zacks Equity Research
HOLX's fiscal 2025 first-quarter results reflect the strength of its Molecular Diagnostics business.
Bio-Techne Tops Q2 Earnings & Revenue Estimates, Stock Up in Premarket
by Zacks Equity Research
TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment.
Trump Tariffs Threaten MedTech: 3 Stocks to Mitigate Risks
by Urmimala Biswas
Three companies that are better positioned to withstand Trump's tariff challenges are ResMed, Hims & Hers Health and Medtronic.
McKesson Stock May Rise With PRISM Vision Holdings Acquisition
by Zacks Equity Research
MCK is set to acquire a controlling stake in PRISM Vision Holdings, aiming to expand its specialty care capabilities and strengthen its leadership in eye health solutions across the United States.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL continues to gain from its robust product portfolio and strong segmental performance.
BSX Q4 Earnings & Revenues Top, Stock Falls on Weak Gross Margin
by Zacks Equity Research
Boston Scientific's fourth-quarter 2024 performance reflects the strength of its core franchises.
Reasons to Retain Inari Medical Stock in Your Portfolio for Now
by Zacks Equity Research
NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.
Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market.
STXS Stock Gains Following the First Order for its GenesisX
by Zacks Equity Research
Stereotaxis receives its first order for the next-generation robotic system, GenesisX. The company expects a full commercial launch in the coming months.
GEHC Stock May Rise With $138M Investment in Cork Facility Expansion
by Zacks Equity Research
GE HealthCare invests $138M to expand its Cork facility to enhance manufacturing capacity for life-saving imaging contrast media and strengthen its global supply chain.
GEHC Stock May Gain on FDA's Nod for the Updated Voluson Expert Series
by Zacks Equity Research
GE HealthCare launches the enhanced Voluson Expert Series to advance women's health with faster, more precise imaging for improved care in obstetrics and gynecology.
Here's Why ResMed (RMD) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
IDEXX Q4 Earnings and Revenues Top Estimates, Stock Up in Pre-Market
by Zacks Equity Research
IDXX delivers better-than-expected earnings and revenues in the fourth quarter of 2024.
ResMed Inc. (RMD) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ResMed Q2 Earnings and Revenues Beat, Stock Up in Pre-Market
by Zacks Equity Research
RMD's stellar second-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.
ANGO Stock Looks Promising on New Ischemia Study for Auryon System
by Zacks Equity Research
AngioDynamics initiates the AMBITION BTK RCT and registry to advance treatment for patients with chronic limb-threatening ischemia and below-the-knee peripheral artery disease.
Compared to Estimates, ResMed (RMD) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ResMed (RMD) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 5.65% and 1.57%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
CAH Q2 Earnings and Sales Beat Estimates, 2025 EPS View Raised
by Zacks Equity Research
Cardinal Health's second-quarter fiscal 2025 results benefit from solid Other segment revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL continues to witness growth on the back of its strong product portfolio.
Here's Why You Should Add PODD Stock to Your Portfolio Now
by Zacks Equity Research
Insulet stays on investors' radar owing to its solid progress with Omnipod 5 and strong solvency position.
Stryker Stock Falls on Deal to Sell Its U.S. Spinal Implants Business
by Zacks Equity Research
SYK announces agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC.
Inogen Stock May Gain on Deal With Yuwell to Expand Global Reach
by Zacks Equity Research
INGN and Yuwell collaborate to expand and enhance Inogen's innovation pipeline through R&D collaboration and accelerate the entry of Inogen's brand into the Chinese market.